FATE — FATE THERAPEUTICS, INC.

Ownership history in JOHNSON & JOHNSON  ·  18 quarters on record

This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in FATE THERAPEUTICS, INC. (FATE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
24.77% (2022 Q1)
Avg. % of fund
7.97%
First filed
2021 Q3
Last filed
2025 Q4
Quarters held
18
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 3,379,064 — 0% 0.60% $3.3M $0.98
2025 Q3 UNCHANGED 3,379,064 — 0% 0.85% $4.3M $1.26
2025 Q2 UNCHANGED 3,379,064 — 0% 1.05% $3.5M $1.12
2025 Q1 UNCHANGED 3,379,064 — 0% 0.78% $2.7M $0.79
14 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    FATE price (monthly, adj. close)

Other funds also holding FATE

As of 2025 Q4 — sorted by position size

Redmile Group, LLC 3Y 7Y 0.93% Bruce & Co., Inc. 3Y 7Y 0.22% Knott David M Jr 3Y 0.17% Monaco Asset Management SAM 3Y 0.14% DAFNA Capital Management LLC 3Y 7Y 0.13% Privium Fund Management B.V. 3Y 0.07% Vestal Point Capital, LP 0.06% TANG CAPITAL MANAGEMENT LLC 3Y 7Y 0.06% Parametrica Management Ltd 3Y 7Y 0.03% GSA CAPITAL PARTNERS LLP 3Y 7Y 0.02%
← Back to JOHNSON & JOHNSON Holdings